Bioceltix S.A. (WSE:BCX)

Poland flag Poland · Delayed Price · Currency is PLN
99.90
+0.10 (0.10%)
Oct 24, 2025, 5:01 PM CET
0.10%
Market Cap491.95M
Revenue (ttm)n/a
Net Income (ttm)-14.00M
Shares Out4.92M
EPS (ttm)-2.84
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,104
Average Volume7,624
Open99.70
Previous Close99.80
Day's Range98.80 - 100.40
52-Week Range71.50 - 129.00
Beta1.26
RSI52.05
Earnings DateNov 27, 2025

About Bioceltix

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 36
Stock Exchange Warsaw Stock Exchange
Ticker Symbol BCX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.